- Home
- NLSP vs MYNZ Comparison
NLSP vs MYNZ Comparison
Compare NLSP & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NLSP
- MYNZ
- Stock Information
- Founded
- NLSP 2015
- MYNZ 2021
- Country
- NLSP Switzerland
- MYNZ Germany
- Employees
- NLSP N/A
- MYNZ N/A
- Industry
- NLSP Biotechnology: Pharmaceutical Preparations
- MYNZ Biotechnology: Pharmaceutical Preparations
- Sector
- NLSP Health Care
- MYNZ Health Care
- Exchange
- NLSP Nasdaq
- MYNZ Nasdaq
- Market Cap
- NLSP 12.4M
- MYNZ 7.9M
- IPO Year
- NLSP 2021
- MYNZ 2021
- Fundamental
- Price
- NLSP $2.15
- MYNZ $1.66
- Analyst Decision
- NLSP
- MYNZ Buy
- Analyst Count
- NLSP 0
- MYNZ 2
- Target Price
- NLSP N/A
- MYNZ $14.00
- AVG Volume (30 Days)
- NLSP 186.7K
- MYNZ 78.6K
- Earning Date
- NLSP 10-17-2025
- MYNZ 10-21-2025
- Dividend Yield
- NLSP N/A
- MYNZ N/A
- EPS Growth
- NLSP N/A
- MYNZ N/A
- EPS
- NLSP N/A
- MYNZ N/A
- Revenue
- NLSP N/A
- MYNZ $893,991.00
- Revenue This Year
- NLSP N/A
- MYNZ $26.06
- Revenue Next Year
- NLSP N/A
- MYNZ $4.97
- P/E Ratio
- NLSP N/A
- MYNZ N/A
- Revenue Growth
- NLSP N/A
- MYNZ N/A
- 52 Week Low
- NLSP $1.30
- MYNZ $1.30
- 52 Week High
- NLSP $6.97
- MYNZ $16.04
- Technical
- Relative Strength Index (RSI)
- NLSP 48.82
- MYNZ 48.08
- Support Level
- NLSP $1.88
- MYNZ $1.58
- Resistance Level
- NLSP $2.02
- MYNZ $1.79
- Average True Range (ATR)
- NLSP 0.14
- MYNZ 0.10
- MACD
- NLSP -0.02
- MYNZ 0.00
- Stochastic Oscillator
- NLSP 33.33
- MYNZ 38.10
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd a clinical-stage biopharmaceutical company focused on the discovery and development of inventive therapies for patients with rare and complex CNS disorders with unmet medical needs. Its compound, mazindol, a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, in a proprietary ER formulation, is being developed for the treatment of narcolepsy, IH (follow-on indication), and potentially ADHD (back-up indication). Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.